Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC-783 in Advanced Solid Tumors
NCT07408258Phase 1Recruiting
- Sponsor
- OncoC4
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONC-783 in pancreatic cancer (PC), ovarian cancer, colorectal cancer (CRC) and 1 more, sponsored by OncoC4. Primary endpoint: Recommended Phase 2 dose at 24 months. Started Aug 2026; status: recruiting.
02
Drugs
ONC-783
03
Conditions
pancreatic cancer (PC)ovarian cancercolorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on NCT07408258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408258.